On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension

Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure) The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension”

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. The study, undertaken to examine the effects of DehydraTECH-CBD upon acute pulmonary hypertension, used a blinded design with administration of a single 300mg dose … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life

Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it Going into 2022, the company … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life”

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion

Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics

Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream DehydraTECH achieves this by bypassing first-pass-liver metabolism By doing so, Lexaria is … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics”

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol (“CBD”) and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction”

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference”

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD”

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study”

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications”

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722